Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Suicidal Behavior, Suicidal Ideation, Ne...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to understand why some people act more impulsively when feeling negative emotions, which is called negative urgency. The researchers hope to understand how negative urgency relates to the way networks of brain cells communicate with one another. The researchers will measure negative urgency and brain signals in adolescents aged 13-21 years with depression and suicidal thoughts and behaviors. The main questions it aims to answer are: * Whether a type of brain signaling called cortical inhibition is related to negative urgency * Whether depressed adolescents with suicidal behavior have more problems with cortical inhibition than depressed adolescents with suicidal thoughts only * Whether the relationship between negative urgency and cortical inhibition changes over time Adolescents who participate in the study will complete the following activities at the time they join the study, as well as 6 months and 12 months later: * Interviews with researchers and questionnaires to learn about their thoughts, emotions, and symptoms * A questionnaire about impulsive behaviors and negative urgency * Computerized games that measure brain functions * An MRI scan of the brain * Transcranial magnetic stimulation with electroencephalography (TMS-EEG), a way to measure how brain cells communicate (cortical inhibition) using a magnet placed outside of the head and recording brain signals

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Single-/paired-pulse transcranial magnetic stimulation — Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.

Primary Outcomes

  • Long-interval intracortical inhibition (LICI) - baseline (Baseline)
  • Long-interval intracortical inhibition (LICI) - 6 months (6 months)
  • Long-interval intracortical inhibition (LICI) - 12 months (12 months)
  • Negative urgency - baseline (Baseline)
  • Negative urgency - 6 months (6 months)
  • Negative urgency - 12 months (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-25
Completion: 2028-01
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Kathryn Cullen, MD (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Charles P Lewis, MD
612-625-4081
lewi1538@umn.edu
Charles Lewis
University of Minnesota
Interventions
  • Other: Single-/paired-pulse transcranial magnetic stimulation — Single-/paired-pulse transcranial magnetic stimulation (sp/ppTMS) is a technique for noninvasive assessment of brain physiology by delivering single or paired magnetic stimuli to the scalp with an electromagnetic coil. This results in transient induction of cortical electrical activity, which can be measured as evoked potentials by electromyography (EMG) and electroencephalography (EEG). Note that sp/ppTMS is used for neurophysiologic measurements; it is distinct from other TMS applications such as repetitive TMS, which can be used as interventions.
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55414 United States
Eligibility Criteria
Inclusion Criteria: * Ages 13-21 years (inclusive) * Any sex, gender, race, or ethnicity * For participants 18 years of age or older, ability to provide written informed consent * For participants under 18 years of age, ability to provide written assent, with legal guardian's ability to provide written informed consent * Ability of participant (and parent/guardian, if applicable) to read and to communicate verbally and in writing in English (in order to permit comprehensive assessment of suicide risk by study team, and to facilitate safety planning and mitigation of suicide-related risks as necessary) * Current diagnosis of a unipolar depressive episode (major depressive episode, unspecified depressive disorder, or adjustment disorder with depressed mood), confirmed on the structured diagnostic interview (MINI or MINI-Kid) * For participants in the Dep/SI group: * Any lifetime history of suicidal ideation, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) * No prior history of suicidal behavior (interrupted attempt, aborted attempt, or suicide attempt) as assessed by the C-SSRS * For participants in the Dep/SB group: \-- Any lifetime history of suicidal behavior (interrupted attempt, aborted attempt, or suicide attempt) as assessed by the C-SSRS * If the study participant will be completing any of the assessments remotely through the use of video teleconferencing, access to a reliable internet connection will be required Exclusion Criteria: * Imminent suicide risk as determined by the PI or other study board-certified child and adolescent psychiatrist (based on review of C-SSRS and SSI scales and clinical assessment of participant) * Current substance use meeting diagnostic criteria for a substance use disorder within the last month on the MINI or MINI-KID diagnostic interview (with the exceptions of caffeine and nicotine) * Lifetime history of psychosis, hypomania, or mania * Historical diagnosis of autism spectrum disorder or intellectual disability * Antiepileptic medication use or chronic benzodiazepine use (as-needed benzodiazepine use will be permitted if it can be held on day of study visit with TMS-EEG testing) * Pregnancy or suspected pregnancy in participants capable of becoming pregnant (assessed with urine pregnancy test) * Medical/neurologic history that would pose increased risks for transcranial magnetic stimulation (TMS) or magnetic resonance imaging (MRI), or factors that would impede completion of study procedures, including: * Neurological disorders including seizure disorder, history of anoxia, history of head injuries with loss of consciousness for greater than 5 minutes * Suicide attempt by hanging or strangulation (asphyxiation) leading to anoxia * Any personal history of seizure or family history of epilepsy * Any metallic implants, fragments, or devices * Any cardiac pacemaker, medication pump, neural stimulator, or other implanted medical device * Risk for increased intracranial pressure (e.g., history of intracranial mass) * History of intracranial surgical procedure * Any contraindication to TMS determined by the TMS Adult Safety Screen (TASS) * Any contraindication to MRI identified on imaging center screening form * Any non-removable hair, head, or neck body modifications that would impede TMS and proper EEG recording
Conditions Breast Neoplasms
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, observational clinical research aimed at establishing a multimodal database encompassing clinical information and gut microbiome data from a sample of over 1,000 breast cancer patients comorbid with depression. The research involves collecting cohort sample information from breast cancer patients with comorbid depression, as well as fecal, blood, and saliva specimens for metagenomic sequencing, untargeted metabolite detection, and cortisol level analysis, respectively. Based on the collected multimodal data, diagnostic, efficacy prediction, and prognostic survival prediction models for breast cancer with comorbid depression will be developed. Additionally, a precision prediction cloud platform will be designed and deployed to support data upload, model prediction, and result visualization.

Design

Study type: Observational Observational model: Other Time perspective: Other

Primary Outcomes

  • objective response rate,ORR (2025-03-11 to 2027-03-01)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-11
Completion: 2027-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xiangya Hospital of Central South University
Contact Information
Study Contact:
Jun Huang,doctor
86-18229944886
404369@csu.edu.cn
Interventions
N/A
Study Locations (1 sites)
Xiangya Hospital of Central South University, Changsha, Hunan 410000 China
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed primary breast cancer; Aged 18-80 years; No prior history of malignancy other than breast cancer; Awareness of their breast cancer diagnosis; Karnofsky Performance Status (KPS) score \>70; Willing to provide blood, fecal, and saliva samples with signed informed consent. Exclusion Criteria: * Physician-diagnosed mental disorders before or after breast cancer diagnosis; Severe chronic somatic diseases (e.g., central nervous system disorders, severe head trauma, substance abuse/dependence, intellectual disability, diabetes, gynecological diseases, cardiovascular diseases, thyroid disorders, etc.); Presence of two or more primary malignancies of different tissue origins; Central nervous system (CNS) metastasis of breast cancer; Clinically diagnosed digestive system diseases (e.g., enteritis, gastritis); Use of antidepressant or anxiolytic therapy during the study; Use of medications that alter gut function or metabolism during the study; Pregnant or lactating women; Radiotherapy or chemotherapy within the past 21 days; Use of antibiotics, probiotics, prebiotics, or synbiotics within 3 months prior to the study; Other reasons deemed unsuitable for participation by investigators.
Conditions Open Angle Glaucoma
Phase PHASE4
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Simbrinza 0.2%-1% Ophthalmic Suspension — brinzolamide and brimonidine tartrate
  • Drug: Rocklatan 0.02%-0.005% Ophthalmic Solution — netarsudil and latanoprost
  • Drug: Cosopt PF 2%-0.5% Ophthalmic Solution — dorzolamide hydrochloride and timolol maleate
  • Drug: Latanoprost 0.005% Ophthalmic Solution — Latanoprost

Primary Outcomes

  • Decrease in mean diurnal IOP (from baseline at week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-05-14
Completion: 2026-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prairie Eye Center
Collaborators: Sengi
Principal Investigators:
  • Sandra Yeh, MD (PRINCIPAL_INVESTIGATOR) - Prairie Eye Center
Contact Information
Study Contact:
Jennifer Lyons
217-257-3102
jenniferlyons37@gmail.com
Jennifer Lyons
217-257-3102
jenniferlyons37@gmail.com
Prairie Eye Center
Sanda Yeh, MD
Prairie Eye Center
Interventions
  • Drug: Simbrinza 0.2%-1% Ophthalmic Suspension — brinzolamide and brimonidine tartrate
  • Drug: Rocklatan 0.02%-0.005% Ophthalmic Solution — netarsudil and latanoprost
  • Drug: Cosopt PF 2%-0.5% Ophthalmic Solution — dorzolamide hydrochloride and timolol maleate
  • Drug: Latanoprost 0.005% Ophthalmic Solution — Latanoprost
Study Locations (1 sites)
Prairie Eye Center, Springfield, Illinois 62704 United States
Eligibility Criteria
Inclusion criteria: * Adults aged Eighteen (18) years and older with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Evidence of optic nerve damage will be based on AAO Preferred Practice Patterns guidelines using either or both of the following: * Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities * Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule * Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc * Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles * Disc rim, parapapillary RNFL, or lamina cribrosa hemorrhages * Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue * Large extent of parapapillary atrophy * Reliable and reproducible visual field abnormality considered a valid representation of the subject's functional status * Visual field damage consistent with RNFL damage (e.g. nasal step, arcuate field defect, or paracentral depression in clusters of test sites) * Visual field loss across the horizontal midline in one hemifield that exceeds loss in the opposite hemifield (in early/ moderate cases) * Absence of other known explanations (e.g. optic disc drusen, optic nerve pit) * Mean diurnal IOP ≥ 18 mmHg and \< 28 mmHg at baseline in at least one eye with an inter-eye IOP difference \< 5 mmHg. * A central corneal thickness (CCT) within the range of 450-650 µm Exclusion criteria: * Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery). * Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT \>1 yr prior to baseline. * Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs. * Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and/ or limit adherence. * Patients with known history or presence of significant ocular diseases including corneal diseases, dystrophies or abnormalities that would prevent accurate IOP readings with GAT. * Patients with a history of uncontrolled IOP with the combination of either Rocklatan + Simbrinza or Cosopt + Latanoprost dual therapy. * Significant ocular surface findings (e.g. hyperemia, irritation) found during slit lamp examination that might affect the study. * Chronic use of any systemic medication for chronic diseases that may affect IOP. * Subjects who are pregnant, lactating or planning a pregnancy. * Any condition in the opinion in the investigator that would potentially confound the results of this study
Conditions Primary Open Angle Glaucoma (POAG), Ocul...
Phase PHASE1, PHASE2
Enrollment 271
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP). REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure. The study is looking at: * What side effects REGN22530 might cause * How much REGN22530 is in the blood and eye fluid at different times * If the body has any reactions to REGN22530 (which may cause REGN22530 to not work as well) * How the body and eye pressure respond after having REGN22530, which can help researchers understand why REGN22530 works better in some people than others * How well REGN22530 works

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: REGN22530 — Administered per the protocol

Primary Outcomes

  • Occurrence of Treatment Emergent Adverse Events (TEAEs) (Up to week 16)
  • Change from baseline in mean diurnal IOP in the study eye (At day 85)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-09-08
Completion: 2029-12-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 271 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Regeneron Pharmaceuticals
Principal Investigators:
  • Clinical Trial Management (STUDY_DIRECTOR) - Regeneron Pharmaceuticals
Contact Information
Study Contact:
Clinical Trials Administrator
844-734-6643
clinicaltrials@regeneron.com
Interventions
  • Drug: REGN22530 — Administered per the protocol
Study Locations (1 sites)
Advanced Research, Deerfield Beach, Florida 33064 United States
Eligibility Criteria
Key Inclusion Criteria: 1. Diagnosis of OHT or POAG of mild to moderate severity as described in the protocol 2. Best-Corrected Visual Acuity (BCVA) of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent of better than or equal to 20/200) in the study eye on day 1 3. BCVA of ≥55 EDTRS letters (Snellen equivalent of better than or equal to 20/80) in the non-study eye on day 1 4. Phakic or pseudophakic with a posterior chamber intraocular lens that has been implanted ≥3 months prior to Screening Visit 1 5. Sufficiently clear ocular media, adequate pupillary dilation and fixation to permit quality posterior segment imaging in the study eye Key Exclusion Criteria: Ocular-specific exclusion criteria apply to the Study Eye only, unless otherwise specified. 1. OAG or OHT secondary to pigment dispersion, pseudoexfoliation, trauma, uveitis, neovascularization, a vascular disorder, or steroid use 2. Congenital or traumatic cataract, or visually significant cataract that is likely to require surgical intervention during the study 3. Presence of significant corneal scarring or irregularities that could interfere with reliable IOP measurement 4. Prior incisional or bleb-forming glaucoma surgery, suprachoroidal procedures, Trabecular Meshwork (TM)-stripping Microinvasive Glaucoma Surgery (MIGS), angle-based implants other than iStent or iridectomy/iridotomy as described in the protocol 5. History of Selective Laser Trabeculoplasty (SLT) within 6 months prior to day 1 6. History of transscleral (including micropulse) or endoscopic cyclophotocoagulation within 1 year prior to day 1 Note: Other protocol defined Inclusion/ Exclusion criteria apply
Conditions Glaucoma, Trabeculectomy, Innovative Pro...
Phase NA
Enrollment 116
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare the efficacy and safety of a novel surgical technique, Innovative Tube Trabeculectomy (ITT), against conventional trabeculectomy in patients with advanced and refractory glaucoma. ITT incorporates a unique preoperative regimen and surgical modifications, including a deep extended scleral tunnel, X-shaped non-absorbable suture, and a nasolacrimal tube implant, designed to enhance aqueous humor outflow and reduce postoperative fibrosis. Participants will be randomized to receive either ITT or conventional trabeculectomy and followed for 12 months to assess intraocular pressure control, medication use, complication rates, and bleb morphology.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Innovative Tube Trabeculectomy — Patients will undergo the innovative tube trabeculectomy procedure. This includes a 3-week preoperative regimen (discontinuation of preserved medications and prostaglandin analogs, initiation of fluorometholone), a 1-week preoperative subconjunctival injection (Mitomycin C 0.04%, Avastin 1.25 mg, Dexamethasone 8 mg), and the surgical technique involving a deep extended scleral tunnel, intraoperative Mitomycin C application, X-shaped non-absorbable suture, and nasolacrimal tube implantation.
  • Procedure: Conventional Trabeculectomy — Patients will undergo standard conventional trabeculectomy with intraoperative Mitomycin C application (concentration and duration as per standard practice at the study site

Primary Outcomes

  • • Measure: Surgical success, defined as Intraocular Pressure (IOP) ≤ 15 mmHg and ≥ 20% reduction from baseline without glaucoma medications. (12 months post-surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-01
Completion: 2028-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 116 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Benha University
Principal Investigators:
  • Tarek Abulnasr, MD (STUDY_DIRECTOR) - Benha University
Contact Information
Study Contact:
Ahmed M Saeed, MD
01227468426
ahmed.abdelhamid@fmed.bu.edu.eg
Mohamed G AlAshhab, MD
0133227518
info@fmed.bu.edu.eg
Ophthalmology department, Faculty of Medicine, Benha University
Tarek Abulnasr, MD
Ophthalmology department, Faculty of Medicine, Benha University
Interventions
  • Procedure: Innovative Tube Trabeculectomy — Patients will undergo the innovative tube trabeculectomy procedure. This includes a 3-week preoperative regimen (discontinuation of preserved medications and prostaglandin analogs, initiation of fluorometholone), a 1-week preoperative subconjunctival injection (Mitomycin C 0.04%, Avastin 1.25 mg, Dexamethasone 8 mg), and the surgical technique involving a deep extended scleral tunnel, intraoperative Mitomycin C application, X-shaped non-absorbable suture, and nasolacrimal tube implantation.
  • Procedure: Conventional Trabeculectomy — Patients will undergo standard conventional trabeculectomy with intraoperative Mitomycin C application (concentration and duration as per standard practice at the study site
Study Locations (1 sites)
Ophthalmology department, Faculty of Medicine, Benha University, Banhā, 13518 Egypt
Eligibility Criteria
Inclusion Criteria: \- • Diagnosis of advanced or refractory primary open-angle glaucoma (POAG) or secondary open-angle glaucoma (excluding neovascular glaucoma). * Intraocular pressure (IOP) \> 21 mmHg despite maximal tolerated medical therapy or previous failed glaucoma surgery. * Best corrected visual acuity (BCVA) of 20/400 or better. * Capable of providing informed consent Exclusion Criteria: * Previous incisional glaucoma surgery in the study eye (except for prior failed trabeculectomy in the refractory group). * Neovascular glaucoma or other forms of secondary glaucoma that may significantly impact wound healing (e.g., uveitic glaucoma). * Significant ocular comorbidities that may confound outcome assessment (e.g., severe corneal disease, retinal detachment). * Pregnancy or lactation. * Participation in another clinical trial within 30 days prior to enrollment.
Conditions High Altitude Pulmonary Hypertension
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis. It represents a significant cause of mortality among high-altitude illnesses due to its swift progression and elevated fatality rates if not addressed promptly. The pathophysiological mechanisms underlying HAPE include excessive hypoxic pulmonary vasoconstriction, increased permeability of the pulmonary vasculature, impaired clearance of fluid from the lungs, and systemic fluid retention. A pivotal factor in HAPE is pulmonary arterial hypertension (PAH), characterized by a progressive rise in pulmonary arterial pressure and resistance, which can ultimately lead to right heart failure. Recent developments in the management of HAPE have introduced inhaled nitric oxide (iNO) as a selective pulmonary vasodilator, which effectively lowers pulmonary arterial pressure and enhances oxygenation without inducing systemic hypotension. The INOwill N300 device, created by Nanjing Novlead Biotech, is a portable iNO delivery system that produces nitric oxide gas on-site, thereby obviating the need for gas cylinders. This device also facilitates real-time monitoring of nitric oxide, nitrogen dioxide, and oxygen concentrations, ensuring safe and effective treatment. This innovative strategy shows potential for improving clinical outcomes in patients with HAPE while addressing logistical challenges encountered in high-altitude environments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Nitric Oxide Generation and Delivery System — The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.

Primary Outcomes

  • Change of Oxygen Index (Through study completion, an average of 5 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-10
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novlead Inc.
Collaborators: Tibet Fokind Hospital
Principal Investigators:
  • Jingxin Cao (PRINCIPAL_INVESTIGATOR) - Tibet Fokind Hospital
Contact Information
Study Contact:
Zhou Fang
15655595707
zhou.fang@novlead.com
Jingxin Cao
Tibet Fokang Hospital
Interventions
  • Device: Nitric Oxide Generation and Delivery System — The Nitric Oxide Generation and Delivery System is used to deliver nitric oxide for inhalation therapy into the inspiratory limb of the patient breathing circuit in a way that provides a constant concentration of nitric oxide (NO), as set by the user, to the patient throughout the inspired breath.
Study Locations (1 sites)
Tibet Fokang Hospital, Lhasa, Tibet China
Eligibility Criteria
Inclusion Criteria: 1. Individuals aged between 18 and 65 years. 2. A score on the Lake Louise Acute Mountain Sickness Scale ranging from 3 to 9 points, as outlined in Annex 2, recorded in 2018. 3. Chest X-ray findings that demonstrate either thickening of the lung texture bilaterally or the presence of nodular opacities in the lower regions of both lungs. 4. Capacity to provide informed consent in accordance with local regulatory requirements. Exclusion Criteria: 1. Confirmed contraindications for the use of nitric oxide include the following (refer to "5.3.4 NO Contraindications"): * Severe hypoplasia of the left heart or duct-dependent congenital heart disease; * Life-threatening congenital anomalies and congestive heart failure; * Congenital methemoglobinemia; * Severe hemorrhagic conditions, including intracranial hemorrhage, intraventricular hemorrhage, and pulmonary hemorrhage. 2. Severe left ventricular dysfunction, characterized by a left ventricular ejection fraction (LVEF) of less than 40%. 3. Pulmonary edema resulting from other cardiac, pulmonary, thoracic, or systemic disorders. 4. Coexistence with high altitude cerebral edema. 5. A history of lung malignancy, lung resection, or lung transplantation. 6. Barotrauma, which may include pneumothorax, subcutaneous and mediastinal emphysema, or the presence of a closed drainage tube in the thoracic cavity. 7. Clinically significant or persistent thrombocytopenia, defined as a platelet count of less than 50×10\^9/L. 8. Administration of pulmonary hypertension medications, such as sildenafil, bosentan, or prostacyclins, within the preceding 30 days. 9. Noncompliance with study protocols and unwillingness to provide informed consent. 10. Any other conditions that the clinician deems render the subject unsuitable for participation in the study.

Progesterone Preeclampsia

NCT07448597
Recruiting
Conditions Preeclampsia, Hypertensive Disorder of P...
Phase PHASE4
Enrollment 642
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Progesterone supplementation — Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.

Primary Outcomes

  • Development of preeclampsia (Antenatally and up to 6 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-13
Completion: 2028-08-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 642 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Contact Information
Study Contact:
Lauren Yacobucci, MD
7163415115
yacobucc@musc.edu
Medical University of South Carolina
Interventions
  • Drug: Progesterone supplementation — Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.
Study Locations (1 sites)
Medical University of South Carolina, Charleston, South Carolina 29401 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant individuals receiving prenatal care at participating clinics * \<12 weeks gestation with a viable intrauterine pregnancy * Age ≥18 years * English-speaking Exclusion Criteria: * Unable or unwilling to self-administer vaginal progesterone * Inability or unwillingness to provide informed consent

Birth & Breastfeeding Support Study

NCT06844019
Recruiting
Conditions Breastfeeding, Breastfeeding Initiation,...
Phase Not Applicable
Enrollment 1628
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn about the effects of birth practices such as cesarean section and vacuum assisted birth and diseases such as gestational diabetes and preeclampsia on exclusive breastfeeding. The main question it aims to answer is: • Does cesarean section, vacuum assisted birth, gestational diabetes and preeclampsia affect exclusive breastfeeding three months after birth? Participants answer eight online survey questions. One survey is distributed before birth and the remaining seven surveys are distributed after birth at three, seven and four-teen days, as well as one, three, six and twelve months after birth.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Exclusive Breastfeeding (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-06
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 1628 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Herlev Hospital
Principal Investigators:
  • Thomas Bergholt, Professor, PhD, MSc (PRINCIPAL_INVESTIGATOR) - Herlev & Gentofte Hospital
Contact Information
Study Contact:
Dorrit Vizel-Schwartz, MSN, CNM, IBCLC, Ph.d.-student
+45 3188 2258
dorrit.vizel-schwartz@regionh.dk
Dorrit Vizel-Schwartz, MSN, CNM, IBCLC Ph.d.-student
+45 3188 2258
dorrit.vizel-schwartz@regionh.dk
Herlev & Gentofte University Hospital
Thomas Bergholt, Professor, PhD, MSc
Herlev & Gentofte University Hospital
Interventions
N/A
Study Locations (1 sites)
Herlev & Gentofte University Hospital, Herlev, 2730 Denmark
Eligibility Criteria
Inclusion Criteria: 18 years, intention to breastfeed, single gestation, reads and understands Danish - Exclusion Criteria: Twin gestation, less than 18 years, no intention to breastfeed, does not read and understand Danish \-
Conditions Pulmonary Arterial Hypertension
Phase PHASE1
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This pilot clinical trial will evaluate the initial safety, feasibility, and pharmacokinetics of microbiota transplant therapy (MTT) with antibiotic pre-conditioning and fiber supplementation vs. placebo in patients with pulmonary arterial hypertension (PAH). This trial will inform development of future trials of MTT as a treatment for PAH. 24 PAH patients will be randomized to receive either MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, or placebo + placebo supplementation. MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week,12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Drug: MTT with antibiotic preconditioning + fiber supplementation — MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
  • Drug: MTT with antibiotic preconditioning + placebo supplementation — MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
  • Other: MTT with placebo + placebo supplementation. — MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.

Primary Outcomes

  • donor engraftment comparison (week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-28
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Principal Investigators:
  • Thenappan Thenappan, MD (PRINCIPAL_INVESTIGATOR) - University of Minnesota
  • Levi Teigen, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Minnesota
  • Alexander Khoruts, MD (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Gretchen Peichel
gpeichel@umn.edu
Gretchen Peichel
University of Minnesota
Interventions
  • Drug: MTT with antibiotic preconditioning + fiber supplementation — MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Fiber supplementation will be 10-14 gm oral fiber supplement. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
  • Drug: MTT with antibiotic preconditioning + placebo supplementation — MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
  • Other: MTT with placebo + placebo supplementation. — MTT will in a capsule form composed of freeze-dried, encapsulated intestinal microbiota from healthy donors. Patients will be followed at week 1, week 2, week 4, week 12, and week 24. Patient will undergo stool sample collection at baseline, week 1, week 4, and week 12, blood sample collection at baseline, week 4, and week, 12. In addition, patient will undergo an echocardiogram, six-minute walk test (6MWT) and quality of life questionnaire at baseline and at week 12.
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55414 United States
Eligibility Criteria
Inclusion Criteria: * Provision of signed and dated consent form * Ages 18-75 * Diagnosis of PAH * On stable treatment for PAH for one month prior to enrollment * Able to swallow capsules * Able to provide blood sample and fecal sample * Stated willingness to comply with all study procedures and availability for the duration of trial to follow-up by telephone, in-person, email, and/or video visits or correspondence. Exclusion Criteria: * Dysphagia to pills * Clinically active inflammatory bowel disease * Pregnancy or breastfeeding. A pregnancy test will be obtained from females of child- bearing potential at the screening visit or day 1 (prior to the receipt of MTT). Patients with a positive pregnancy test will be excluded. A negative result will be required for subjects who are females of child-bearing potential to receive MTT. Patients will be counseled to avoid pregnancy which is the standard of care for patients with PAH. * Life expectancy of \< 6 months * Presence of ileostomy or colostomy * Patients on immunosuppressants (calcineurin inhibitors, prednisone ≥ 20 mg/day, methotrexate, azathioprine, immunosuppressive biologics, JAK inhibitors). * Patients with neutropenia (an absolute neutrophil count \< 0.5 x 10 9 cells/L) obtained on a complete blood count with differential at screening * History of solid organ or bone marrow transplant * Anticipated recurrent antibiotic use (patients with frequent urinary tract infections or sinusitis) * History of severe anaphylactic food allergy * History of celiac disease * Patients receiving cancer chemotherapy, immunotherapy, or radiation * Patients with severe Irritable bowel syndrome (IBS) defined by an IBS score \>250
Conditions Intrahepatic Bile Duct Cancer, Intrahepa...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if additional chemotherapy by means of a chemo pump can prevent return of disease in adult patients with bile duct cancer in the liver that can be treated with surgery. The main questions it aims to answer are: * Does addition of chemotherapy by means of a chemo pump lead to less return of disease within the liver two years after surgery? * Does addition of chemotherapy by means of a chemo pump lead to longer survival of patients? * Does addition of chemotherapy by means of a chemo pump lead to an increase in quality of life? Participants will receive an implanted chemo pump, through which additional chemotherapy will be given to the liver in addition to surgery.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Combination Product: Hepatic Arterial Infusion Pump chemotherapy with floxuridin — Participants in this arm will receive in addition to standard care (surgery) a chemo pump. This pump will provide participants with 4 cycles of treatment with chemotherapy (Floxuridin), each lasting 4 weeks. Total treatment with chemotherapy will last 16 weeks (approx. 4 months)

Primary Outcomes

  • Two-year hepatic recurrence free survival (hRFS) (From pump implantation until 2 years after that surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-11-20
Completion: 2033-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Erasmus Medical Center
Collaborators: Koningin Wilhelmina Fonds
Principal Investigators:
  • Bas Groot Koerkamp, MD, PhD (PRINCIPAL_INVESTIGATOR) - Erasmus Medical Center
Contact Information
Study Contact:
Bas Groot Koerkamp, MD, PhD
+31(0)107031810
b.grootkoerkamp@erasmusmc.nl
Thomas C Zwaan, MD
+31(0)621218051
t.zwaan@erasmusmc.nl
Bas Groot Koerkamp, MD, PhD
+31(0)107031810
b.grootkoerkamp@erasmusmc.nl
Erasmus Medical Center
Interventions
  • Combination Product: Hepatic Arterial Infusion Pump chemotherapy with floxuridin — Participants in this arm will receive in addition to standard care (surgery) a chemo pump. This pump will provide participants with 4 cycles of treatment with chemotherapy (Floxuridin), each lasting 4 weeks. Total treatment with chemotherapy will last 16 weeks (approx. 4 months)
Study Locations (1 sites)
Erasmus Medical Center, Rotterdam, South Holland 3015GD Netherlands
Eligibility Criteria
Inclusion Criteria: * 18 years or older * ECOG or WHO performance status 0 or 1 * Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care. * Patient is able to undergo a laparotomy. * Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement. * Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old) * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^ 9/L * White blood cell count (WBC) ≥ 2.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Glomerular filtration rate (GFR) ≥ 30 ml/min * Haemoglobin (Hb) ≥ 5.5 mmol/L * Total bilirubin ≤ 25 µmol/L * Written informed consent must be given according to ICH/good clinical practice (GCP), and national/local regulations. Exclusion Criteria: * Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible. * Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years. * Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency * Prior hepatic radiation, ablation, or resection for iCCA. * Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed. * (Partial) portal vein thrombosis in future liver remnant. * Pregnant or lactating women. * History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy. * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator. * Organ allografts requiring immunosuppressive therapy. * Serious infections (uncontrolled or requiring treatment). * Participation in another interventional study for iCCA with survival as outcome. * Participation in another prospective study with an interventional medical product. * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Conditions Pre-Eclampsia, Preeclampsia
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to assess and analyze volume status in preeclamptic patients and compare these parameters with those of normotensive pregnant ones based on the change in internal jugular vein ultrasound-based indices.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Measuring internal jugular vein (IJV) collapsibility index (Intra-operative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanta University
Contact Information
Study Contact:
Abdelghany AA Mohamed, MBBCH
+201123676274
Aldomiaty97@gmail.com
Hospital
Tanta University Hospital
U
Tanta University Hospital
Interventions
N/A
Study Locations (1 sites)
Tanta University Hospital, Tanta, El-Gharbia Govenorate 31527 Egypt
Eligibility Criteria
Inclusion Criteria: 1. Singleton parturients from 18 to 40 years old. 2. Either normotensive or preeclamptic parturients scheduled for elective cesarean section under neuro-axial block matched for gestational age 28-40 weeks will be included: 3. Normotensive group: uncomplicated normotensive pregnancy with systolic blood pressure below 140 mmHg and diastolic blood pressure below 90mmHg without proteinuria. 4. Preeclamptic Group: new onset preeclamptic pregnant female with gestational hypertension after 20 weeks of pregnancy diagnosed based on ISSHP Guidelines: systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg, accompanied by one or more of the following: * Proteinuria (≥300 mg in a 24-hour urine sample) * Alb/Cr ratio ≥30 mg/mmol, * Organ dysfunction (renal insufficiency (creatinine level\>1.1mg%), liver involvement (liver enzyme levels ≥3 times normal), neurological complications (Headache and blurring of vision) and hematological involvement (thrombocytopenia\<100.000)). Exclusion Criteria: 1. Parturients with pre-existing cardiac \& vascular disease affecting blood volume and vascular compliance: (Valvular or congenital heart disease, arrhythmia, previous history of venous thromboembolism, chronic kidney disease, gestational diabetes). 2. multiple gestations 3. known thyroid disorders or chronic hypertension 4. patients with BMI \>40 and patients requiring emergency delivery.
Conditions Pulmonary Hypertension, Interstitial Lun...
Phase PHASE3
Enrollment 344
Locations 185 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-05
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Treprostinil Palmitil Inhalation Powder — Oral inhalation using a capsule-based dry powder inhaler device.
  • Drug: Placebo — Oral inhalation using a capsule-based dry powder inhaler device.

Primary Outcomes

  • Change in 6 Minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 24 (Baseline, Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-01-07
Completion: 2028-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 344 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insmed Incorporated
Principal Investigators:
  • Study Director (STUDY_DIRECTOR) - Insmed Incorporated
Contact Information
Study Contact:
Insmed Medical Information
18444467633
medicalinformation@insmed.com
Interventions
  • Drug: Treprostinil Palmitil Inhalation Powder — Oral inhalation using a capsule-based dry powder inhaler device.
  • Drug: Placebo — Oral inhalation using a capsule-based dry powder inhaler device.
Study Locations (185 sites)
USA027, Phoenix, Arizona 85013 United States
USA007, Fresno, California 93720 United States
USA010, Los Angeles, California 900275969 United States
USA023, Los Angeles, California 90095 United States
USA020, San Francisco, California 94143 United States
USA001, Santa Barbara, California 93105-4349 United States
USA017, Gainesville, Florida 32610 United States
USA006, Naples, Florida 34102-5412 United States
USA026, St. Petersburg, Florida 33707-6129 United States
USA028, Tampa, Florida 33606 United States
Eligibility Criteria
Inclusion Criteria * Diagnosis of PH World Health Organisation (WHO) Group 3 associated with ILD \[including but not limited to idiopathic interstitial pneumonia (IIP), chronic hypersensitivity pneumonitis (HSP), connective tissue disease-associated interstitial lung disease (CTD-ILD), combined pulmonary fibrosis and emphysema (CPFE). * Confirmation of fibrotic interstitial lung disease by centrally overread computed tomography (CT) scan performed at Screening or within prior 12 months. * PH confirmed by right heart catheterization (RHC) at Screening or within 12 months prior to Screening, with the following hemodynamic findings: * Mean pulmonary arterial pressure (mPAP) \>20 millimetre of mercury (mmHg) and * Pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg and * Pulmonary vascular resistance (PVR) ≥4 wood units (WU). * 6 Minute walking distance (6MWD) ≥100 and ≤500 meters at two 6 minute walking test (6MWT)s at Screening performed at least 4 hours apart, with the difference between the 2 distances ≤15%. * Participants receiving chronic medication for underlying disease (e.g., antifibrotic, immunomodulators, immunosuppressants, etc.) and/or phosphodiesterase 5 (PDE5) inhibitors, should be on this treatment for ≥90 days and on a stable dose for ≥30 days prior to Screening. * Capable of giving signed informed consent as described in Section 10.1.5 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion criteria * Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5 (including sarcoidosis), or subtypes of PH WHO Group 3 other than interstitial lung disease. * Primary diagnosis of chronic obstructive pulmonary disease (COPD) and/or forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) \<0.7 (based on screening or historical spirometry within the prior 6 months). * Clinically significant left heart disease: * evidence of clinically significant left-sided valvular heart disease, * left ventricular failure with left ventricular ejection fraction (LVEF) \<45% * echocardiography findings at Screening suggestive for postcapillary (or combined pre and postcapillary) PH, heart failure with preserved ejection fraction (HFpEF), or heart failure with mildly reduced ejection fraction (HFmrEF), including left atrial volume index (LAVI) \>34 millilitres per metre square (mL/m\^2) * unstable ischemic heart disease * unstable arrhythmia, including uncontrolled atrial fibrillation (rate-controlled arrhythmia or paroxysmal atrial fibrillation is allowed) * Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism. * Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine). * Current use of cigarettes or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes either every day or some days. * Current use of inhaled marijuana, recreational or medical (current use defined as used at least one or more times during the past 30 days prior to Screening) or expected use during the study. * Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease and/or may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial. Note: Other protocol defined inclusion/exclusion criteria may apply.